Terms: = Lung cancer AND HERPUD1, ENSG00000051108, 9709, Q15011, SUP, Mif1, KIAA0025, HERP AND Treatment
11 results:
1. Reconstruction-Assisted Feature Encoding Network for Histologic Subtype Classification of Non-Small Cell lung cancer.
Li H; Song Q; Gui D; Wang M; Min X; Li A
IEEE J Biomed Health Inform; 2022 Sep; 26(9):4563-4574. PubMed ID: 35849680
[TBL] [Abstract] [Full Text] [Related]
2. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
Wang C; Zhang X; Li H; Li X; Lin Y
PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
[TBL] [Abstract] [Full Text] [Related]
3. Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell lung cancer.
Chisaki Y; Nakamura N; Yano Y
Biol Pharm Bull; 2017; 40(1):73-81. PubMed ID: 28049952
[TBL] [Abstract] [Full Text] [Related]
4. treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.
Ceccon M; Mologni L; Giudici G; Piazza R; Pirola A; Fontana D; Gambacorti-Passerini C
Mol Cancer Res; 2015 Apr; 13(4):775-83. PubMed ID: 25421750
[TBL] [Abstract] [Full Text] [Related]
5. suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis.
Bode C; Kinjo T; Alvord WG; Klinman DM
Carcinogenesis; 2014 May; 35(5):1078-83. PubMed ID: 24403310
[TBL] [Abstract] [Full Text] [Related]
6. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
[TBL] [Abstract] [Full Text] [Related]
7. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract] [Full Text] [Related]
8. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
[TBL] [Abstract] [Full Text] [Related]
9. Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response.
Joo JH; Liao G; Collins JB; Grissom SF; Jetten AM
Cancer Res; 2007 Aug; 67(16):7929-36. PubMed ID: 17699800
[TBL] [Abstract] [Full Text] [Related]
10. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract] [Full Text] [Related]
11. Role of cytokines in distribution and differentiation of dendritic cell/Langerhans' cell lineage in human primary carcinomas of the lung.
Colasante A; Castrilli G; Aiello FB; Brunetti M; Musiani P
Hum Pathol; 1995 Aug; 26(8):866-72. PubMed ID: 7635448
[TBL] [Abstract] [Full Text] [Related]
